BioMarin to Acquire Inozyme Pharma for USD 270 Million

BioMarin Pharmaceutical, Inc. has publicly disclosed a definitive agreement to acquire Inozyme Pharma, Inc in an all-cash transaction of nearly USD 270 million. As per the agreement, BioMarin will purchase shares for USD 4.00 each and the deal was accepted by both companies’ boards without objection. Completion of the deal is likely to take place in the third quarter of 2025 after obtaining regulatory approvals and complying with customary closing conditions.

Key Takeaways:

• BioMarin to acquire Inozyme Pharma in an all-cash deal worth $270 million.
• Deal adds late-stage ENPP1 deficiency therapy INZ-701 to BioMarin’s pipeline.
• Transaction expected to close in Q3 2025, pending regulatory approvals.

This acquisition will expand BioMarin’s enzyme therapy portfolio with the addition of INZ-701, the world’s first and only enzyme replacement therapy considered to be in the late stages of development for treating ENPP1 deficiency - a rare progressive genetic disease that leads to the degeneration of the cardiovascular system, bones, and soft tissues. There are no approved therapies for this disorder which is known for causing high infant mortality combined with severe skeletal complications from early childhood through multiple stages of life.

Also read: Three Crucial Benefits of Leveraging Real-World Evidence in Pharma

Alexander Hardy, president and chief executive officer of BioMarin said, "BioMarin has been deeply committed to advancing enzyme therapies for children and adults living with serious genetic conditions for more than 25 years, and today's agreement builds on our legacy. This acquisition brings to BioMarin an important medicine that has the potential to be the first treatment for children and adults with ENPP1 deficiency, improving care for people living with this serious condition. As BioMarin continues our transformation and delivers on our corporate strategy, we will continue to evaluate external innovation alongside internal innovation. We are in a strong financial position to bring in additional assets as we accelerate the development of medicines for patients with significant unmet need.”

Douglas A. Treco, Ph.D., chief executive officer and chairman of Inozyme said, "Today's announcement gives greater hope to patients who may benefit from INZ-701, a potentially transformative therapy that aims to address the underlying causes and systemic impacts of ENPP1 deficiency. BioMarin has paved the way over the past two and a half decades, successfully launching five first-in-disease enzyme therapies. I'd like to thank the team at Inozyme and our partners for their outstanding work and dedication, as we pass this important potentially life-changing therapy to the leading innovator in genetically defined conditions."